These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
406 related articles for article (PubMed ID: 34766424)
1. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. Butt JH; Docherty KF; Jhund PS; de Boer RA; Böhm M; Desai AS; Howlett JG; Inzucchi SE; Kosiborod MN; Martinez FA; Nicolau JC; Petrie MC; Ponikowski P; Bengtsson O; Langkilde AM; Schou M; Sjöstrand M; Solomon SD; Sabatine MS; McMurray JJV; Køber L Eur J Heart Fail; 2022 Mar; 24(3):513-525. PubMed ID: 34766424 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial. Butt JH; Docherty KF; Petrie MC; Schou M; Kosiborod MN; O'Meara E; Katova T; Ljungman CEA; Diez M; Ogunniyi MO; Langkilde AM; Sjöstrand M; Lindholm D; Bengtsson O; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Jhund PS; McMurray JJV; Køber L JAMA Cardiol; 2021 Jun; 6(6):678-689. PubMed ID: 33787831 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction. Docherty KF; Ogunniyi MO; Anand IS; Desai AS; Diez M; Howlett JG; Nicolau JC; O'Meara E; Verma S; Inzucchi SE; Køber L; Kosiborod MN; Lindholm D; Martinez FA; Bengtsson O; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Langkilde AM; Jhund PS; McMurray JJV JACC Heart Fail; 2022 Jan; 10(1):52-64. PubMed ID: 34969498 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. Butt JH; Nicolau JC; Verma S; Docherty KF; Petrie MC; Inzucchi SE; Schou M; Kosiborod MN; Langkilde AM; Martinez FA; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Bengtsson O; Jhund PS; McMurray JJV; Køber L Eur J Heart Fail; 2021 Apr; 23(4):601-613. PubMed ID: 33594755 [TBL] [Abstract][Full Text] [Related]
6. Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF. Butt JH; Dewan P; DeFilippis EM; Biering-Sørensen T; Docherty KF; Jhund PS; Kosiborod MN; Martinez FA; Bengtsson O; Johansen ND; Langkilde AM; Sjöstrand M; Vaduganathan M; Solomon SD; Sabatine MS; Køber L; Fiuzat M; McMurray JJV JACC Heart Fail; 2022 Aug; 10(8):543-555. PubMed ID: 35902157 [TBL] [Abstract][Full Text] [Related]
7. Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. Docherty KF; Jhund PS; Anand I; Bengtsson O; Böhm M; de Boer RA; DeMets DL; Desai AS; Drozdz J; Howlett J; Inzucchi SE; Johanson P; Katova T; Køber L; Kosiborod MN; Langkilde AM; Lindholm D; Martinez FA; Merkely B; Nicolau JC; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Tereshchenko S; Verma S; McMurray JJV Circulation; 2020 Oct; 142(17):1623-1632. PubMed ID: 32883108 [TBL] [Abstract][Full Text] [Related]
8. Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial. Solomon SD; Jhund PS; Claggett BL; Dewan P; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Inzucchi SE; Desai AS; Bengtsson O; Lindholm D; Sjostrand M; Langkilde AM; McMurray JJV JACC Heart Fail; 2020 Oct; 8(10):811-818. PubMed ID: 32653447 [TBL] [Abstract][Full Text] [Related]
9. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. Zelniker TA; Bonaca MP; Furtado RHM; Mosenzon O; Kuder JF; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Budaj A; Kiss RG; Padilla F; Gause-Nilsson I; Langkilde AM; Raz I; Sabatine MS; Wiviott SD Circulation; 2020 Apr; 141(15):1227-1234. PubMed ID: 31983236 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. Martinez FA; Serenelli M; Nicolau JC; Petrie MC; Chiang CE; Tereshchenko S; Solomon SD; Inzucchi SE; Køber L; Kosiborod MN; Ponikowski P; Sabatine MS; DeMets DL; Dutkiewicz-Piasecka M; Bengtsson O; Sjöstrand M; Langkilde AM; Jhund PS; McMurray JJV Circulation; 2020 Jan; 141(2):100-111. PubMed ID: 31736328 [TBL] [Abstract][Full Text] [Related]
11. Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER. Wang X; Vaduganathan M; Claggett BL; Hegde SM; Pabon M; Kulac IJ; Vardeny O; O'Meara E; Zieroth S; Katova T; McGrath MM; Pouleur AC; Jhund PS; Desai AS; Inzucchi SE; Kosiborod MN; de Boer RA; Kober L; Sabatine MS; Martinez FA; Ponikowski P; Shah SJ; Hernandez AF; Langkilde AM; McMurray JJV; Solomon SD; Lam CSP Circulation; 2023 Feb; 147(8):624-634. PubMed ID: 36342789 [TBL] [Abstract][Full Text] [Related]
12. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. Docherty KF; Anand IS; Chiang CE; Chopra VK; Desai AS; Kitakaze M; Verma S; Vinh PN; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Bengtsson O; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Langkilde AM; Jhund PS; McMurray JJV JACC Asia; 2022 Apr; 2(2):139-153. PubMed ID: 36339117 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF. Dewan P; Solomon SD; Jhund PS; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; DeMets DL; Sabatine MS; Bengtsson O; Sjöstrand M; Langkilde AM; Anand IS; Bělohlávek J; Chopra VK; Dukát A; Kitakaze M; Merkely B; O'Meara E; Schou M; Vinh PN; McMurray JJV; Eur J Heart Fail; 2020 Jul; 22(7):1247-1258. PubMed ID: 32539224 [TBL] [Abstract][Full Text] [Related]
14. Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction. Butt JH; Kondo T; Jhund PS; Comin-Colet J; de Boer RA; Desai AS; Hernandez AF; Inzucchi SE; Janssens SP; Kosiborod MN; Lam CSP; Langkilde AM; Lindholm D; Martinez F; Petersson M; Shah SJ; Thierer J; Vaduganathan M; Verma S; Wilderäng U; Claggett BC; Solomon SD; McMurray JJV J Am Coll Cardiol; 2022 Nov; 80(18):1705-1717. PubMed ID: 36041668 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER. Kondo T; Butt JH; Curtain JP; Jhund PS; Docherty KF; Claggett BL; Vaduganathan M; Bachus E; Hernandez AF; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Kosiborod MN; Desai AS; Køber L; Ponikowski P; Sabatine MS; Solomon SD; McMurray JJV Circ Heart Fail; 2023 Dec; 16(12):e010898. PubMed ID: 37886880 [TBL] [Abstract][Full Text] [Related]
16. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial. Kosiborod MN; Jhund PS; Docherty KF; Diez M; Petrie MC; Verma S; Nicolau JC; Merkely B; Kitakaze M; DeMets DL; Inzucchi SE; Køber L; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Bengtsson O; Lindholm D; Niklasson A; Sjöstrand M; Langkilde AM; McMurray JJV Circulation; 2020 Jan; 141(2):90-99. PubMed ID: 31736335 [TBL] [Abstract][Full Text] [Related]
17. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. Berg DD; Jhund PS; Docherty KF; Murphy SA; Verma S; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Bengtsson O; Ponikowski P; Sjöstrand M; Solomon SD; McMurray JJV; Sabatine MS JAMA Cardiol; 2021 May; 6(5):499-507. PubMed ID: 33595593 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. Jhund PS; Solomon SD; Docherty KF; Heerspink HJL; Anand IS; Böhm M; Chopra V; de Boer RA; Desai AS; Ge J; Kitakaze M; Merkley B; O'Meara E; Shou M; Tereshchenko S; Verma S; Vinh PN; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Bengtsson O; Langkilde AM; Sjöstrand M; McMurray JJV Circulation; 2021 Jan; 143(4):298-309. PubMed ID: 33040613 [TBL] [Abstract][Full Text] [Related]
19. Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF. Dewan P; Docherty KF; Bengtsson O; de Boer RA; Desai AS; Drozdz J; Hawkins NM; Inzucchi SE; Kitakaze M; Køber L; Kosiborod MN; Langkilde AM; Lindholm D; Martinez FA; Merkely B; Petrie MC; Ponikowski P; Sabatine MS; Schou M; Sjöstrand M; Solomon SD; Verma S; Jhund PS; McMurray JJV Eur J Heart Fail; 2021 Apr; 23(4):632-643. PubMed ID: 33368858 [TBL] [Abstract][Full Text] [Related]